L 806978

Drug Profile

L 806978

Latest Information Update: 13 Mar 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Naphthyridines; Osteoporosis therapies
  • Mechanism of Action Bone resorption factor inhibitors; Integrin alphaVbeta3 antagonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Osteoporosis

Most Recent Events

  • 13 Mar 2003 No development reported - Preclinical for Osteoporosis in USA (unspecified route)
  • 15 Sep 2000 Preclinical development for Osteoporosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top